CAR-T therapy has huge market development space, which is attracting domestic pharmaceutical companies to actively explore

In recent years, there have been two major breakthroughs in the field of immunotherapy, namely PD-1/PD-L1 inhibitors and CAR-T cell therapy
.
Among them, the treatment of CAR-T cell therapy drugs is mainly to transfer CAR-T cells cultured in vitro to the human body.
By activating T cells to attack and kill tumor cells in the patient, it is a very effective immunotherapy method
.
Because of the great potential of cell gene therapy in cancer treatment, the market for CAR-T cell therapy has obviously become more and more broad in recent years
.
It is worth noting that, facing the considerable market prospects, pharmaceutical companies have begun to accelerate their exploration in the field of CAR-T cell therapy
.
At present, there are a total of 5 CAR-T drugs approved for marketing worldwide.
Novartis’ Kymriah was approved for marketing earlier, and the approval date was August 2017
.
Two months later, Yescarta of Kite, a subsidiary of Gilead, was approved for listing in the United States in October 2017, becoming another CAR-T cell therapy approved for listing in the world
.
With the approval of these two products on the market, CAR-T cell therapy has become more popular, and it has also given everyone more hope of curing tumors
.
At present, although only two products have been approved for marketing in China, they are Akilunzai introduced by Fosun Kate and Ruiji Orenzai developed by WuXi Juno based on JCAR017 of Juno in the United States
.
But in fact, domestic pharmaceutical companies have been actively deploying CAR-T cell therapy drugs in recent years
.
Incomplete statistics show that at present the country has 24 pharmaceutical companies CAR-T layout therapies, including Fosun Kate, drug giant Connaught Ming, legendary creature, Cozi creatures, reindeer medical, biological Xi Biman, Cinda biology
.
It is worth mentioning that in the near future, some companies have disclosed the company's new progress for CAR-T therapy
.
For example, on November 15th, Keji Pharmaceuticals announced that the company’s CT041 has been granted priority drug qualification (PRIME) by the European Medicines Agency (EMA) for the treatment of gastric cancer/gastric junction cancer
.
Keji Pharmaceutical pointed out that CT041 is a candidate for autologous CAR-T targeting CLDN18.
2.
It believes that CT041 is expected to become the backbone therapy in the treatment of gastric and pancreatic cancer worldwide
.
In July, the listing application of WuXi's Noreji Orencil injection (relma-cel) has also entered the "pending approval" status, and it is expected to be approved as a new domestic CAR-T product
.
Public information shows that WuXi Juno CD19 CAR-T Ruiji Oronza (JWCAR029) is a CAR-T product independently developed by WuXi Juno based on JCAR017 of Juno in the United States
.
Previously, it was included in the limited approval for the treatment of relapsed or refractory large B-cell lymphoma in adult patients after second-line or above systemic therapy
.
In June, at the 2021 American Society of Clinical Oncology (ASCO) annual meeting, Sibman Bio also announced the new CD19/CD20 dual-target CAR-T cell therapy C-CAR039 and CD20 CAR-T cell therapy C-CAR066.
According to new clinical research data, these two new CAR-T therapies are expected to bring new hope to patients with relapsed/refractory B-cell non-Hodgkin's lymphoma
.
In general, more and more pharmaceutical companies' CAR-T products have been approved and clinically one after another, which fully shows that the current domestic pharmaceutical companies' enthusiasm for exploring CAR-T therapy is constantly rising
.
It is reported that up to now, the number of CAR-T clinical trials carried out in China has exceeded 500, ranking the forefront in the world.
This is the first time that China has reached the international forefront in a new drug research and development field
.
Following this trend, with the opening of the first year of China's cell therapy and the continuous influx of capital, the scale of the entire CAR-T cell therapy market will continue to expand
.
The industry predicts that the CAR-T cell market will grow at an annual rate of 20.
2% and will be worth US$20.
3 billion by 2027
.